Guillain-Barré syndrome following the second dose of COVID AstraZeneca vaccine in a 78-year-old male: a case report from Nepal
Open Access
- 17 February 2023
- journal article
- case report
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (3) , 498-501
Abstract
Introduction and Importance: Guillain-Barré syndrome (GBS) is a rare acute idiopathic demyelinating polyneuropathy that causes bilateral, symmetrical, and progressive weakness of muscles. AstraZeneca vaccine is a genetically modified spike glycoprotein vaccine of an adenovirus vector. GBS following the second dose of the AstraZeneca vaccine dose is rare and not frequently noted. Case Presentation: A 78-year-old male presented to the hospital with complaints of bilateral weakness of the lower limbs over 4 days following the second dose of the AstraZeneca vaccine. On examination, the power and tone of the limbs were diminished. The sensitivity pinprick test revealed low sensitivity in the right lower limb than in the left lower limb. Nerve conduction studies revealed acute inflammatory demyelinating polyneuropathy and the patient was diagnosed with GBS. After admission, the patient was successfully treated with intravenous immunoglobulins along with physiotherapy. Clinical Discussion: GBS can be diagnosed clinically with nerve conduction studies and Brighton’s criteria. The robust causal relationships between COVID-19 infections, COVID-19 vaccination, and GBS are still unclear. The evaluation of the potential association and risk of GBS with vaccines warrants the need for precise post-vaccination surveillance measures and results. Conclusion: Only a few cases of GBS following the second dose of AstraZeneca are reported so far and there is a need for strong and accurate diagnosis of the disease and proper post-vaccination surveillance for the evaluation of risk associated with COVID vaccines.Keywords
This publication has 14 references indexed in Scilit:
- Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 VaccinationAnnals of Neurology, 2021
- Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical TrialNeurology, 2021
- Guillain-Barré syndromeThe Lancet, 2021
- Nerve conduction studies in Guillain-Barré syndrome: Influence of timing and value of repeated measurementsJournal of the Neurological Sciences, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) GuidelinesInternational Journal of Surgery, 2020
- Significance of Brighton Criteria in the Early Diagnosis and Management of Guillain-Barré SyndromeCureus, 2020
- Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisNature Reviews Neurology, 2014
- Vaccines and Guillain-Barré SyndromeDrug Safety, 2009
- Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain–Barré syndromeJournal of Neuroimmunology, 2005